Methods and Systems for Optimizing Refractive Refraction of Human Eyes

    公开(公告)号:US20240206722A1

    公开(公告)日:2024-06-27

    申请号:US18557796

    申请日:2022-04-27

    IPC分类号: A61B3/028 A61B3/10 A61B3/103

    摘要: Methods and systems are disclosed for optimizing refractive prescriptions of human eyes. First, objective refraction devices such as aberrometers and auto-refractors will not only provide an objective estimate of sphero-cylinder correction, but also a quality metrics for at least one of a) measuring the confidence level in the objectively determined cylinder power and cylinder axis in addition to the objective sphero-cylinder correction, b) assessing/displaying quality of vision corrections for a plurality of cylinder power. Second, the quality metrics will be used to elect one of a plurality of modes of subjective refraction with a phoropter: 1) one mode for the subjective determination of spherical power only, 2) another mode for subjective determination of both sphere power and cylinder power.

    METHODS AND DEVICES FOR WAVEFRONT TREATMENTS OF ASTIGMATISM, COMA, PRESBYOPIA IN HUMAN EYES

    公开(公告)号:US20220211489A1

    公开(公告)日:2022-07-07

    申请号:US17611298

    申请日:2020-04-09

    IPC分类号: A61F2/16 A61F9/008 G02C7/04

    摘要: Methods and devices are provided for wavefront treatments of an eye's astigmatism, coma, and presbyopia. Wavefront-engineered monofocal lenses, inducing spherical aberration into the eye's central pupil, provide vision correction beyond 20/20 acuity and improve quality of vision by eliminating image distortion caused by uncorrected astigmatism and coma in the eye. New presbyopia-correcting lenses, including Extended Depth of Focus (EDOF) bifocal, EDOF trifocal, and quasi-accommodating lenses, are disclosed for presbyopia corrections between +0.75 D to +3.25 D, and they are achieved by inducing a positive spherical aberration and a positive focus offset less than 3 Diopters in a central section plus a negative spherical aberration in an annular section within a central part of a monofocal lens. These wavefront lenses can be adapted for contact lenses, implantable contact lenses, Intraocular Lenses (IOLs), phakic IOLs, accommodating IOLs, corneal inlays, as well as eyepieces for Virtual Reality (VR) displays, game goggles, microscopes, telescopes.

    SYSTEMS FOR SELF-REFRACTION AND REMOTE EYE EXAMS OF HUMAN EYES

    公开(公告)号:US20240206723A1

    公开(公告)日:2024-06-27

    申请号:US18557113

    申请日:2022-04-27

    IPC分类号: A61B3/028 A61B3/00 A61B3/032

    摘要: A refraction system for remote refraction or self-refraction of human eyes. The system uses a reliable spherocylindrical module that allows the refraction system to obtain an initial spherocylindrical correction of the eye, and an SPH adjustment module that allows the user to adjust spherical power of the phoropter module on top of the initial spherocylindrical correction of the eye so that an updated spherical power (SPH) is subjectively determined. The reliable spherocylindrical module can be I) a device for obtaining a prescription of a pair of old eyeglasses, or II) a wavefront aberrometer that can offer, in addition to the objective sphero-cylinder correction, a quality metrics for at least one of a) measuring the confidence level in the objectively determined cylinder power and cylinder axis, b) assessing/displaying quality of vision corrections for a plurality of cylinder power.

    Methods and systems of optical diagnosis for refractive eye exams

    公开(公告)号:US11998271B2

    公开(公告)日:2024-06-04

    申请号:US17285449

    申请日:2018-10-25

    摘要: Methods and systems am disclosed in which an optical diagnosis of an eye's optical image quality is performed using a simulated retinal image. An objective measurement of a total wave aberration is obtained, and residual aberrations are computed by subtracting a sphero-cylindrical correction from the total wave aberration. The simulated retinal image is computed by computing a point-spread function from the residual aberrations and convolving the computed point-spread function with an acuity chart. The optical diagnosis includes at least one of: determining excess aberrations, ranking optics of the eye into optical grades, selecting the eye for high-definition eyeglasses, identifying amblyopia or macular diseases, or choosing an objective refraction for vision correction.

    Device to machine communications
    8.
    发明授权

    公开(公告)号:US09749856B2

    公开(公告)日:2017-08-29

    申请号:US14409767

    申请日:2012-06-20

    摘要: Methods and apparatuses for providing services for a mobile device with access to a cellular system are disclosed. In accordance with a method a mobile device sends to a cellular system a request for a service by a machine type device. The request includes information identifying the machine type device for use by the cellular system that is then used in exchange of information in relation to at least one of authentication, authorization and configuration. Information associated with configuration of a device-to-machine connection to the machine type device is then sent to the mobile device. The device-to-machine connection for use of the service is then established between the machine type device and the mobile device based on the received information. In another embodiment the mobile device contact the machine type device first and provides the machine type device with information assigned by the cellular system.

    METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94
    10.
    发明申请
    METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 审中-公开
    使用特异性GRP94抗体治疗肿瘤的方法

    公开(公告)号:US20140234324A1

    公开(公告)日:2014-08-21

    申请号:US14268925

    申请日:2014-05-02

    摘要: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.

    摘要翻译: 本文公开了对治疗肿瘤具有协同作用的药剂的组合。 这些药剂组合可用于治疗肿瘤,其中癌细胞表达突变的BRAF。 公开了用于治疗诊断患有表达突变型BRAF的肿瘤的受试者的方法。 所述方法包括向受试者(1)施用治疗有效量的特异性结合葡萄糖调节蛋白(GRP)94的抗体或其抗原结合片段; 和(2)治疗有效量的BRAF抑制剂。 在一些实施方案中,肿瘤是黑素瘤。 在一些实施方案中,该方法包括选择具有对BRAF抑制剂的一级或二级抗性的受试者。 在另外的实施方案中,治疗肿瘤包括减少肿瘤的转移。 在另外的实施方案中,BRAF抑制剂包括PLX4032或PLX4720。